AAI Pharma's Lee Karras talks about contract-service demand. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AAI Pharma's Lee Karras talks about contract-service demand.

Pharmaceutical Technology
Volume 34, Issue 1, pp. 72

Q&A with Lee Karras, CEO of AAI Pharma

PharmTech:
What is the biggest industry challenge you're now facing?



Karras:
Without question, slowing demand for contract services. A decrease in venture-capital (VC) funding for startup and biotechnology companies and thin pipelines in Big Pharma have resulted in short-term stagnation of demand for contract development and manufacturing organizations (CDMOs) and for contract manufacturing organizations (CMOs). We have shifted our short-term focus to supporting more commercial products and focusing on the lines of business that are more or less unaffected by the slowdown such as clinical packaging and distribution, formulation technologies, and parenteral manufacturing. In the long run, we feel that VC funding and pharmaceutical outsourcing will return to normal levels because history indicates that the industry is cyclical in nature.

PharmTech:
How do you stay abreast of new developments in the industry?

Karras:
We listen carefully to our customers because they know better than anyone what the industry is looking for and what new trends are emerging. The industry is seeking novel dosage forms, potent compounds, clinical packaging, and drug-delivery technologies.

PharmTech:
Do you see a new industry trend emerging?

Karras:
Consolidation is a trend we have seen in the contract research industry and will likely see in the CDMO and CMO spaces. Many undercapitalized companies will look to consolidate as the pace of growth slows in the CDMO and CMO spaces.

PharmTech:
What is the most common demand your clients are making of you?

Karras:
Now, with the economic downturn and decrease in VC funding, the demands are economic in nature. Price concessions, extended terms, and creative deal-making are becoming more common.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here